Can I Take Omega-3 (EPA/DHA) With Tranexamic Acid? A Women's Health Guide

What Is the Actual Interaction Between Omega-3 and Tranexamic Acid?

The interaction between EPA/DHA and tranexamic acid is pharmacodynamic, not pharmacokinetic. That means the two substances do not meaningfully alter each other's absorption, metabolism, or elimination. What they do is pull in opposite directions on blood clotting.

Tranexamic acid is a synthetic lysine analog that blocks plasminogen from binding to fibrin, which prevents the breakdown of blood clots already formed. The Lancet published data from the WOMAN trial showing tranexamic acid reduces death from postpartum hemorrhage when given within three hours of bleeding onset, confirming its primary mechanism is antifibrinolytic rather than procoagulant in the classic sense.

Omega-3 fatty acids, particularly EPA (eicosapentaenoic acid), reduce platelet aggregation by competing with arachidonic acid in the cyclooxygenase and thromboxane A2 pathways. A 2020 review in JACC confirmed that high-dose EPA supplementation (4 g/day, as in the REDUCE-IT trial) is associated with a small but real increase in atrial fibrillation and a modest antiplatelet effect. At the doses most women take for general cardiovascular or anti-inflammatory support (1-2 g/day total EPA+DHA), that antiplatelet signal is much weaker.

Why This Matters for Heavy Menstrual Bleeding

If you are taking oral tranexamic acid (Lysteda, 1,300 mg three times daily for up to five days per cycle) to control heavy menstrual bleeding, adding a high-dose omega-3 supplement could blunt the drug's ability to reduce menstrual blood loss. The practical concern is not a catastrophic bleed. It is that you might see less improvement in your period volume than expected.

Why This Matters for Melasma

Women using low-dose oral tranexamic acid for melasma (typically 250 mg twice daily, an off-label dose studied in Southeast Asian dermatology trials) are on a much lower antifibrinolytic burden. A 2020 systematic review in the Journal of the American Academy of Dermatology found tranexamic acid at 250 mg twice daily reduced melasma area and severity index (MASI) scores by roughly 50% over 12 weeks. At that low dose, the pharmacodynamic tension with standard omega-3 supplementation is even smaller. The interaction concern shifts almost entirely to the HMB clinical picture.

How Omega-3s Work on Platelets: The Mechanism in Plain Language

EPA competes directly with arachidonic acid for the COX-1 enzyme. When EPA wins that competition, the platelet produces thromboxane A3 instead of thromboxane A2. Thromboxane A3 is a far weaker platelet activator. The net result is reduced platelet stickiness.

This is not the same mechanism as aspirin, which permanently acetylates COX-1. Omega-3's antiplatelet effect is dose-dependent and reversible. A meta-analysis in Prostaglandins, Leukotrienes and Essential Fatty Acids found that doses below 3 g/day EPA+DHA produced no statistically significant change in bleeding time in healthy adults.

The Dose Line That Matters

| EPA+DHA Daily Dose | Antiplatelet Signal | Clinical Concern With Tranexamic Acid | |---|---|---| | <1 g/day | Negligible | None expected | | 1-3 g/day | Minimal | Low; monitor for breakthrough bleeding | | 3-4 g/day | Mild to moderate | Moderate; discuss with prescriber | | >4 g/day (prescription strength) | Clinically meaningful | Requires prescriber review before combining |

Prescription omega-3 products like icosapent ethyl (Vascepa, 4 g/day) or omega-3-acid ethyl esters (Lovaza, 4 g/day) cross the threshold where the conversation with your prescriber is not optional.

Women-Specific Physiology: Why Your Cycle and Hormonal Status Change the Picture

Women are not a homogeneous group, and your hormonal environment actively modifies both platelet function and fibrinolysis. Here is how this plays out across life stages.

Reproductive Years and Menstrual Cycle Fluctuations

Platelet aggregation varies across the menstrual cycle. Estrogen generally promotes a pro-coagulant state, while progesterone's effect is more neutral. Research published in Thrombosis and Haemostasis showed platelet count and aggregation are measurably higher in the luteal phase. This means that if you take omega-3s and tranexamic acid together, the pharmacodynamic tension between them could shift slightly depending on where you are in your cycle, though this has not been studied directly in a clinical trial.

For women with heavy menstrual bleeding linked to PCOS, who may be prescribed tranexamic acid to manage anovulatory bleeding, high-dose omega-3 supplementation is also often discussed for its triglyceride-lowering effects. PCOS is associated with hypertriglyceridemia in a significant portion of women, and a Cochrane review on omega-3 in PCOS found meaningful reductions in triglycerides and LDL cholesterol. So the supplement has real metabolic reasons to be used in this population, which makes the concurrent use pattern more common than clinicians might assume.

Perimenopause

During perimenopause, estrogen levels fluctuate widely, and fibrinolytic balance shifts. Some perimenopausal women are prescribed tranexamic acid for the erratic heavy bleeding that characterizes this transition. Many are also reaching for omega-3 supplements for mood, cardiovascular protection, and joint comfort. The combination is extremely common in this age group and has not been studied prospectively.

The Menopause Society's 2023 position statement on nonhormonal therapies does not specifically address omega-3 and tranexamic acid co-use, but recommends regular reassessment of all supplements in perimenopausal women given the shifting hemostatic profile.

Postpartum

In the postpartum period, tranexamic acid is sometimes used to reduce secondary postpartum hemorrhage. Omega-3 supplementation is also common postpartum given interest in DHA for both mood and infant brain development if breastfeeding. The pharmacodynamic concern remains, but most postpartum women are not taking omega-3 at doses above 3 g/day, keeping the practical risk low.

Pregnancy and Lactation Safety: What You Need to Know

Tranexamic acid in pregnancy. Tranexamic acid is not assigned a formal FDA pregnancy letter category under the current labeling system (which moved away from A-D-X categories), but animal studies show no teratogenicity and it crosses the placenta. Human data are largely derived from use in obstetric hemorrhage contexts, where its benefit is well established. The WOMAN trial enrolled postpartum women and demonstrated a mortality benefit with early tranexamic acid in hemorrhage. Oral tranexamic acid for elective indications (melasma, cyclical HMB management) should be avoided during the first trimester unless your provider has made a specific benefit-risk determination. There is no established safe oral dose for elective use in pregnancy.

Contraception requirement. If you are of reproductive age and taking oral tranexamic acid for melasma or HMB, your prescriber should confirm contraception status. Tranexamic acid is not a teratogen with the evidence base of, say, isotretinoin, but its elective oral use is not appropriate during pregnancy.

Omega-3 in pregnancy. EPA/DHA supplementation is actively encouraged during pregnancy and lactation by ACOG, particularly DHA at 200-300 mg/day for fetal brain development. There is no interaction concern between omega-3 and tranexamic acid specifically in the obstetric hemorrhage context where intravenous tranexamic acid is given acutely.

Lactation. Tranexamic acid does transfer into breast milk. A small pharmacokinetic study found milk-to-plasma ratios of approximately 1% of the maternal plasma concentration, which is considered a negligible infant dose. The World Health Organization and most lactation databases classify tranexamic acid as compatible with breastfeeding at therapeutic doses. Omega-3 supplementation during lactation is considered safe and beneficial for infant DHA delivery. No interaction concern exists between omega-3 and tranexamic acid in the breastfeeding context.

Female-Relevant Conditions Where Both Are Used Together

Several conditions common in women put tranexamic acid and omega-3 use on a collision course. Knowing your specific clinical context helps you and your provider make the right call.

PCOS

Women with PCOS face a double burden: anovulatory heavy bleeding that may prompt tranexamic acid use, and hypertriglyceridemia that makes omega-3 supplementation a reasonable metabolic strategy. Approximately 70% of women with PCOS have some degree of dyslipidemia. If your omega-3 dose is below 2 g/day EPA+DHA, continuing both while monitoring menstrual blood loss is a reasonable approach.

Endometriosis and Fibroids

Heavy menstrual bleeding from endometriosis or fibroids is one of the more common reasons tranexamic acid is prescribed to reproductive-age women. Some women with these conditions also take anti-inflammatory doses of omega-3 (typically 2-3 g/day EPA) for pain modulation, based on evidence that EPA competes with arachidonic acid to reduce prostaglandin E2 production. A 2011 randomized controlled trial in Gynecologic and Obstetric Investigation found EPA supplementation reduced dysmenorrhea scores over three months. This is precisely the dose range where monitoring menstrual blood loss with concurrent tranexamic acid becomes important.

Melasma in Perimenopausal and Postmenopausal Women

Oral tranexamic acid for melasma is growing in popularity across age groups, but perimenopausal women with melasma worsened by hormonal fluctuation are a specific subgroup. Many are already taking omega-3 for cardiovascular and cognitive reasons. At the 250 mg twice-daily dermatology dose of tranexamic acid, the antifibrinolytic load is low enough that standard omega-3 supplementation (1-2 g/day) is not expected to reduce efficacy.

What to Do If You Are Already Taking Both

If you are currently taking omega-3 supplements alongside tranexamic acid, here is a practical framework.

Step 1. Quantify your omega-3 dose. Add up the total EPA+DHA milligrams per day from all sources (fish oil capsules, algal oil, flaxseed oil does not count as it is ALA, not EPA/DHA). If you are below 2 g/day, the pharmacodynamic concern is low.

Step 2. Track your menstrual blood loss. If you are using tranexamic acid for HMB, a simple pictorial blood assessment chart (PBAC) can tell you whether your bleeding is adequately controlled. A PBAC score above 100 per cycle correlates with blood loss greater than 80 mL and indicates inadequate control.

Step 3. Tell your prescriber. The interaction is not listed as contraindicated in any major drug interaction database, but your prescriber cannot weigh it if they do not know you are taking both.

Step 4. Consider timing. There is no formal dose-separation window that eliminates this pharmacodynamic interaction (unlike pharmacokinetic interactions where separating by two hours changes absorption). Taking them hours apart does not reduce the effect. The variable that matters is omega-3 dose.

Step 5. If you are on prescription-strength omega-3 (4 g/day icosapent ethyl or omega-3-acid ethyl esters) and also taking tranexamic acid for HMB, a prescriber-led review is warranted. These two uses simultaneously represent a clinically meaningful scenario that requires individual benefit-risk assessment.

Who This Is Right For, and Who Should Be More Careful

Lower concern (monitoring only)

• Women taking tranexamic acid 250 mg twice daily for melasma and 1-2 g/day omega-3 for general health
• Women taking Lysteda 1,300 mg three times daily for five days per cycle and less than 2 g/day EPA+DHA
• Postpartum women using tranexamic acid for secondary hemorrhage prevention at standard doses with typical DHA supplementation for lactation

Greater caution warranted

• Women on prescription-strength icosapent ethyl (4 g/day) for hypertriglyceridemia who are also using tranexamic acid for HMB. This combination warrants a specific conversation about alternatives for HMB such as hormonal IUD (Mirena), which reduces HMB without the antifibrinolytic mechanism
• Women with a history of thromboembolic disease who are prescribed tranexamic acid should also consult before adding any dose of omega-3 above standard supplement ranges, given the complexity of their clotting history
• Women with known bleeding disorders (von Willebrand disease type 1 is the most common in women, affecting approximately 1% of the general population) who use tranexamic acid as a cornerstone therapy should be particularly attentive to anything that could blunt its effect, including high-dose omega-3

Evidence Gaps: What We Do Not Know

Women have been historically underrepresented in pharmacology trials, and this interaction is no exception. There is no published randomized controlled trial examining the effect of omega-3 supplementation on tranexamic acid efficacy in women with HMB. The antiplatelet effect of omega-3 has been studied mainly in cardiovascular populations that skew male.

The REDUCE-IT trial, which used 4 g/day icosapent ethyl and demonstrated a 25% relative risk reduction in major cardiovascular events, enrolled only about 28% women. The antiplatelet signal observed in that trial cannot be cleanly extrapolated to a female-dominant HMB or melasma population taking lower doses.

What is directly studied: tranexamic acid's efficacy in HMB (the ECLIPSE trial compared it favorably to mefenamic acid), omega-3's antiplatelet mechanism in vitro and in cardiovascular populations, and individual PK data for tranexamic acid in women of reproductive age. What is extrapolated: the clinical magnitude of their combined pharmacodynamic effect on menstrual blood loss in any specific woman.

This honesty matters. Your clinician should not dismiss the concern as zero, nor overstate it as a hard contraindication.

Monitoring Parameters If You Continue Both

If you and your provider decide to continue both, track these:

• Menstrual blood loss using a validated tool like the PBAC score each cycle you use tranexamic acid
• Bleeding symptoms outside of menses (easy bruising, prolonged bleeding from cuts) at your next visit, particularly if your omega-3 dose is above 2 g/day
• Triglycerides if you are taking omega-3 for dyslipidemia in PCOS or metabolic syndrome; your omega-3 dose may need to stay higher for metabolic benefit, requiring a frank conversation about switching HMB management strategy
• Blood pressure is not directly relevant to this interaction but is worth noting in women taking tranexamic acid long-term for melasma, as a case series in the Journal of Dermatological Treatment flagged thromboembolic risk signals at higher cumulative doses